Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4320-4330

  Kožíšek, Milan ^a   Henke, Sandra ^b   Šašková, Klára Grantz ^a   Jacobs, Graeme Brendon ^b   Schuch, Anita ^b   Buchholz, Bernd ^c   Müller, Viktor ^d   Kräusslich, Hans Georg ^e   Řezáčová, Pavlína ^a,f   Konvalinka, Jan ^a   Bodem, Jochen ^b,e  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; PROTEINASE;

ARTICLE; CATALYSIS; ENZYME ANALYSIS; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS STRAIN;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, GAG; GENES, POL; HEK293 CELLS; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 84864383508     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00465-12     Document Type: Article

References (46)

1. Adachi A, et al. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291. (Pubitemid 16013975)
2. Balode D, Westman M, Kolupajeva T, Rozentale B, Albert J. 2010. Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia. J. Med. Virol. 82:2013-2018.
3. Bartonova V, et al. 2008. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Res. 78:275-277.
4. Betts MJ, Sternberg MJ. 1999. An analysis of conformational changes on protein-protein association: implications for predictive docking. Protein Eng. 12:271-283. (Pubitemid 29209937)
5. Brynda J, et al. 2004. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. Acta Crystallogr. D Biol. Crystallogr. 60:1943-1948. (Pubitemid 41087523)
6. Castro E, et al. 2010. HIV-1 drug resistance transmission networks in southwest Switzerland. AIDS Res. Hum. Retroviruses 26:1233-1238.
7. Cígler P, et al. 2005. From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc. Natl. Acad. Sci. U. S. A. 102:15394-15399. (Pubitemid 41528068)
8. Cote HC, Brumme ZL, Harrigan PR. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594. (Pubitemid 32037261)
9. Dam E, et al. 2009. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 5:e1000345. doi:10.1371/journal.ppat.1000345.
10. Delaugerre C, et al. 2004. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir. Ther. 9:415-421. (Pubitemid 38878757)
11. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132. (Pubitemid 41742764)
12. Frentz D, et al. 2010. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One 5:e11505. doi:10.1371/journal.pone.0011505.
13. Grant P, et al. 2009. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Clin. Infect. Dis. 48:680-682.
14. Ho SK, et al. 2008. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 378:272-281.
15. Jain V, et al. 2010. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 5:e15510. doi: 10.1371/journal.pone.0015510.
16. King NM, et al. 2004. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78:12012-12021. (Pubitemid 39390785)
17. Kolli M, Lastere S, Schiffer CA. 2006. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 347:405-409.
18. Kozisek M, et al. 2008. Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region. J. Virol. 82:5869-5878. (Pubitemid 351822261)
19. Lescar J, et al. 1999. Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci. 8:2686-2696. (Pubitemid 30007630)
20. Li KB. 2003. ClustalW-MPI: ClustalW analysis using distributed and parallel computing. Bioinformatics 19:1585-1586.
21. Little KE, Bland RM, Newell ML. 2008. Vertically acquired paediatric HIV infection: the challenges of providing comprehensive packages of care in resource-limited settings. Trop. Med. Int. Health 13:1098-1110.
22. Mammano F, Petit C, Clavel F. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72:7632-7637. (Pubitemid 28377901)
23. Mammano F, Trouplin V, Zennou V, Clavel F. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74:8524-8531. (Pubitemid 30666703)
24. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M. 2006. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes. Acta Crystallogr. D Biol. Crystallogr. 62:859-866. (Pubitemid 44125661)
25. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53:240-255. (Pubitemid 27235885)
26. Muzammil S, Ross P, Freire E. 2003. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42:631-638. (Pubitemid 36133287)
27. Myint L, et al. 2004. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antivir. Chem. Chemother. 48:444-452. (Pubitemid 38141700)
28. Nijhuis M, et al. 2007.Anovel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4:e36. doi:10.1371/journal.pmed.0040036.
29. Obermeier M, et al. 2012. HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology 55:102-107.
30. Richards AD, et al. 1990. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J. Biol. Chem. 265:7733-7736.
31. Sanches M, et al. 2007. Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development. J. Mol. Biol. 369:1029-1040. (Pubitemid 46754060)
32. Saskova KG, et al. 2008. Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. Protein Sci. 17:1555-1564.
33. Saskova KG, et al. 2009. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J. Virol. 83:8810-8818.
34. Shen L, et al. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766. (Pubitemid 351951518)
35. Tebit DM, Zekeng L, Kaptue L, Kräusslich HG, Herchenröder O. 2003. Construction and characterisation of a full-length infectious molecular clone from a fast replicating, X4-tropic HIV-1 CRF02.AG primary isolate. Virology 313:645-652. (Pubitemid 37040702)
36. Thompson MA, et al. 2010. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304:321-333.
37. US Department of Health and Human Services. 14 October 2011, posting date. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services, Washington, DC.
38. Vaclavikova J, et al. 2005. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression. Acta Virol. 49:29-36. (Pubitemid 47046831)
39. Vagin A, Teplyakov A. 2000. An approach to multi-copy search in molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 56:1622-1624.
40. van Maarseveen NM, et al. 2012. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. Retrovirology 9:29. doi:10.1186/1742-4690-9-29.
41. van Maarseveen NM, et al. 2007. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J. Infect. Dis. 195:399-409.
42. Velazquez-Campoy A, et al. 2003. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr. Drug Targets Infect. Disord. 3:311-328. (Pubitemid 38016620)
43. Wang J, Bambara RA, Demeter LM, Dykes C. 2010. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions. J. Virol. 84:9377-9389.
44. Weber J, et al. 2002. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. J. Mol. Biol. 324:739-754. (Pubitemid 36044110)
45. Williams JW, Morrison JF. 1979. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63:437-467.
46. Youmans E, Tripathi A, Albrecht H, Gibson JJ, Duffus WA. 2011. Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. South Med. J. 104:95-101.